These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 12012017)

  • 1. The influence of the suppression of gastrooesophageal reflux on the gene expression pattern in Barrett's oesophagus.
    Menges M; Michaeli B; Pueschel W; Zeitz M; Meese E
    Int J Oncol; 2002 Jun; 20(6):1323-9. PubMed ID: 12012017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease.
    Shearer C; Going J; Neilson L; Mackay C; Stuart RC
    Histopathology; 2005 Sep; 47(3):268-75. PubMed ID: 16115227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
    Jankowski JA; Anderson M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
    Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus.
    Vallböhmer D; DeMeester SR; Oh DS; Banki F; Kuramochi H; Shimizu D; Hagen JA; Danenberg KD; Danenberg PV; Chandrasoma PT; Peters JH; DeMeester TR
    Am J Gastroenterol; 2006 Jul; 101(7):1458-66. PubMed ID: 16863546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
    De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
    Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
    Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
    Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2006 Sep; 38(9):643-8. PubMed ID: 16627016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
    Todd JA; Basu KK; de Caestecker JS
    Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
    Cooper BT; Chapman W; Neumann CS; Gearty JC
    Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the composition of gastric reflux bile acids on Barrett's oesophagus.
    Takahashi Y; Amano Y; Yuki T; Mishima Y; Tamagawa Y; Uno G; Ishimura N; Sato S; Ishihara S; Kinoshita Y
    Dig Liver Dis; 2011 Sep; 43(9):692-7. PubMed ID: 21466977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the clinical significance of stromal angiogenesis in Barrett's esophagus?
    Moriyama N; Amano Y; Mishima Y; Okita K; Takahashi Y; Yuki T; Ishimura N; Ishihara S; Kinoshita Y
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S210-5. PubMed ID: 19120900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
    Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Association between symptomatic gastroesophageal reflux and Barrett's esophagus].
    Trujillo-Benavides OE; Baltazar-Montúfar P; Angeles-Garay U; Ramírez-Mendoza P; Navarro-García AM; Paredes-Cruz E; Méndez del Monte R; Guerrero-Hernández M
    Rev Gastroenterol Mex; 2005; 70(1):14-9. PubMed ID: 16170957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dickkopf homologs in squamous mucosa of esophagitis patients are overexpressed compared with Barrett's patients and healthy controls.
    Ali I; Rafiee P; Hogan WJ; Jacob HJ; Komorowski RA; Haasler GB; Shaker R
    Am J Gastroenterol; 2006 Jul; 101(7):1437-48. PubMed ID: 16863544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.
    El-Serag HB; Aguirre T; Kuebeler M; Sampliner RE
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1255-60. PubMed ID: 15191506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.